A5046740826- MicroRNA in disease regulation
- RNA Research and Splicing
- S100 Proteins and Annexins
- Cell Adhesion Molecules Research
- Cancer, Hypoxia, and Metabolism
- Advanced biosensing and bioanalysis techniques
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- RNA modifications and cancer
- Acute Kidney Injury Research
- RNA Interference and Gene Delivery
- Angiogenesis and VEGF in Cancer
- Extracellular vesicles in disease
- Blood Coagulation and Thrombosis Mechanisms
- Glutathione Transferases and Polymorphisms
- Immune Response and Inflammation
- RNA and protein synthesis mechanisms
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer Research and Treatments
- CRISPR and Genetic Engineering
University of Puerto Rico, Medical Sciences Campus
2018-2022
University of Puerto Rico System
2020-2022
Glioblastoma (GBM) is the most common and lethal of central nervous system (CNS) malignancies. The initiation, progression, infiltration ability GBMs are attributed in part to dysregulation microRNAs (miRNAs). Thus, targeting dysregulated miRNAs with RNA oligonucleotides (RNA interference, RNAi) has been proposed for GBM treatment. Despite promising results laboratory, have clinical limitations that include poor stability off-target effects. RNAi therapies against confront an additional...
Cumulating evidence indicates that dysregulation of microRNAs (miRNAs) plays a central role in the initiation, progression, and drug resistance cancer cells. However, specific miRNAs contributing to ovarian cells have not been fully elucidated. Aimed identify potential involved platinum resistance, we performed miRNA expression profile cisplatin-sensitive cisplatin-resistant cells, found several differentially abundant pair cell lines. Notably, miR-18a-5p (miR-18a), member oncogenic...
Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop platinum-resistant disease poor prognosis. Although reports suggest that integrin-linked kinase (ILK) is a potential target for treatment, identification of ILK downstream effectors has not been fully explored. The purpose this study was investigate the molecular biological effects targeting in cisplatin-resistant cancer. Western blot...
Inflammatory Breast Cancer (IBC) is an aggressive form of invasive breast cancer, highly metastatic, representing 2–4% all cancer cases in the United States. Despite its rare nature, IBC responsible for 7–10% deaths, with a 5-year survival rate 40%. Thus, targeted and effective therapies against are needed. Here, we proposed Lipocalin-2 (LCN2)—a secreted glycoprotein aberrantly abundant different cancers—as plausible target IBC. In immunoblotting, observed higher LCN2 protein levels cells...
Worldwide, the number of cancer-related deaths continues to increase due ability cancer cells become chemotherapy-resistant and metastasize. For women with ovarian cancer, a staggering 70% will resistant front-line therapy, cisplatin. Although many mechanisms cisplatin resistance have been proposed, key such remain elusive. The RNA binding protein multiple splicing (RBPMS) binds nascent transcripts regulates splicing, transport, localization, stability. Evidence indicates that RBPMS also...
Abstract RNA-Binding Protein with Multiple Splicing (RBPMS) is a member of family proteins that bind to the nascent RNA transcripts and regulate their processing, which includes pre-mRNA splicing transport/localization/stability molecule. Evidence indicates RBPMS also binds members AP-1 (c-Jun c-Fos) transcription factor repressing his activity. Until now, little known about biological function in ovarian cancer. To understand role cancer we generated CRISPR (clustered regularly interspaced...
RNA interference is a therapeutic modality in which molecules, such as small RNAs (siRNAs) and microRNAs (miRNAs) (inhibitors mimics), are used to regulate the expression of target mRNAs. MiRNAs multitargeting molecules that involved regulation several targets can therefore influence multiple pathways when deregulated. On other hand, siRNAs repress specific gene by sequence complementarity mRNA. Although both miRNAs have an increasing potential, systemic delivery RNA‐based technologies...
Despite good responses to first‐line treatment with platinum‐based chemotherapy such as cisplatin, most ovarian cancer patients will relapse and eventually develop chemoresistant disease poor prognosis. Therefore, new therapies targeting key survival pathways are urgently needed for this deadly disease. Increased levels of integrin‐linked kinase (ILK), a serine/threonine adaptor protein, have been well documented in various types cancers including cancer. Our previous findings indicate that...
Abstract Platinum-based therapy remains as the front-line treatment for ovarian cancer. However, despite initial response to treatment, most patients develop platinum resistance and eventually succumb malignancy. In an attempt identify novel targets in cisplatin-resistant cancer, we studied role of microRNA-18a-5p (miR-18a) miR-18a is part vastly researched miR-17-92 cluster. Although members this cluster have been associated with pro-tumorigenic roles several cancers, recent findings...